News - Page 6 of 12 - Leukaemia Care

9th July 2021

Lack of awareness of COVID-19 protection puts up to half a million at risk

Leukaemia Care is 1 of 16 health charities who is calling on the Government to do more to support around half a million people who are immunocompromised or immunosuppressed, and so may be less protected by the Covid-19 vaccine.

2nd July 2021

Booster jabs for the clinically extremely vulnerable – what does this mean for me?

The Joint Committee on Vaccines and Immunisations (JCVI) have published draft recommendations on the use of third vaccine doses as booster jabs. Here, we update you on what this means for blood cancer patients.

7th June 2021

The SMC recommends aclabrutinib to become a treatment option for certain groups of CLL patients in Scotland.

The Scottish Medicines Consortium (SMC) have today made recommendations for acalabrutinib to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in Scotland.

25th May 2021

The latest from BSH

Here, we bring you the latest updates from the British Society of Haematology (BSH) conference.

23rd March 2021

Reflecting on the last year

Today is National Day of Reflection, in this article we look back on the last 12 months and showcase what we have achieved.

18th March 2021

Acalabrutinib to become a treatment option for certain groups of CLL patients in England

The National Institute for Health and Care Excellence (NICE) have made recommendations for acalabrutinib to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in England.

17th March 2021

Leukaemia Care’s response to the pausing of shielding on the 31stof March

Today, it was confirmed that shielding in England will once again be paused on the 31stof March. Here is our response to the news

11th March 2021

Call for review of COVID vaccine timings for blood cancer patients

Following the publication of emerging evidence that the Pfizer COVID vaccines are less effective for cancer patients after a single dose, the Blood Cancer Alliance (BCA) has today written to the Joint Committee on Vaccination and Immunisation (JCVI) asking them to review the case for a reduction in the 12-week delay between vaccination doses for blood cancer patients.

7th December 2020

SMC approves venetoclax with obinutuzumab for some patients with untreated CLL

The Scottish Medicines Consortium (SMC) have today made recommendations for venetoclax plus obinutuzumab to become a treatment option for certain groups of chronic lymphocytic leukaemia (CLL) patients in Scotland.

10th November 2020

NICE approves venetoclax with obinutuzumab for patients with untreated CLL

The National Institute for Health and Care Excellence (NICE) have made recommendations for venetoclax plus obinutuzumab as an option for chronic lymphocytic leukaemia (CLL) patients in England.